CME online

in association with the 10th Heart in Diabetes (HiD)

The DCRM Patient

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by:
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 1 Credits ™.
Accreditation period: August 15, 2026 – August 15, 2027

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be emailed to you upon satisfactory completion of these documents.

The DCRM Patient
Agenda

Introduction, Pre-CME Questions & A Case: The Complex CRM Patient
Stephen J. Greene, MD

Prevention and Management of CRM Complications – Focused on Obesity
Neha J. Pagidipati, MD, MPH

Hard to Control HTN – Is it Resistant HTN?
Raymond R. Townsend, MD

Kidney Impact on Co-Morbidities – Approach to Treatment
Peter Rossing, MD, DMSc

Addressing Heart Failure in DCRM Diseases
Stephen J. Greene, MD

Panel Discussion and Q&A: The DCRM Patient – Where to Start?
Moderator: Yehuda Handelsman, MD
Panel: Stephen J. Greene, MD • Neha J. Pagidipati, MD, MPH • Peter Rossing, MD, DMSc • Raymond R. Townsend, MD

Post-CME Questions & Concluding Remarks

Faculty

Yehuda Handelsman, MD, ChairFACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Adjunct Clinical Professor of Medicine
Charles Drew University, Los Angeles, CA
Chair, Scientific Advisory Board, DCMi –
Diabetes CardioRenal & Metabolism Institute
Tarzana, California

Stephen J. Greene, MD, ChairFACC, FHFSA

Associate Professor of Medicine, Division of Cardiology
Co-Director, Duke Heart Failure Medication Titration Clinic
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Neha J. Pagidipati, MD, MPH

Associate Professor, Division of Cardiology
Duke University School of Medicine
Director, Duke Cardiometabolic Prevention Clinic
Duke Clinical Research Institute
Durham, North Carolina

Raymond R. Townsend, MD, FAHA

Professor of Medicine
Associate Director
The Clinical and Translational Research Center
University of Pennsylvania
Philadelphia, Pennsylvania

Peter Rossing, MD, DMSc

Professor, Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark

Program Description

Obesity is central in cardiorenal-metabolic (CRM) diseases driving DM, HTN, CKD, HF, MASLD, ASCVD, and cancers- contributing to ~1.6 million premature deaths globally. Evidence increasingly supports incretin-based therapies across CRM conditions. HTN, affecting 1.4 billion adults, with resistant HTN—common in obesity and CKD—posing additional risk. Excess aldosterone drives resistant HTN and kidney fibrosis; novel selective aldosterone synthase inhibitors, alone and with SGLT2 inhibitors, show promise. Integrated, evidence-based strategies are essential across obesity and CRM conditions. This symposium will address the challenges in diagnosis and management of patients with complex & multiple CRM diseases.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Discuss the contributions of obesity to cardiorenal and metabolic comorbidities
  • Recognize new pathways and emerging treatment options for hypertension and resistant hypertension
  • Explore connection between CKD, HF and other CRM conditions, along with implications for treatment
  • Describe the differential diagnosis of cardiomyopathy, HFpEF, and HFrEF and appropriate treatment for each form of HF

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Creighton University and Metabolic Endocrine Education Foundation (MEEF). Creighton Health Sciences Continuing Education (HSCE) is accredited by the ACCME to provide continuing medical education for physicians. Administrated by the Metabolic Institute of America.

    Creighton Health Sciences Continuing Education (HSCE) designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).

    For information please contact: [email protected] or 818 342 1889 This is a CME Program Supported by an Educational Grant from Astrazeneca